Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Practical Measures of Ruxolitinib’s Clinical Benefit

Clin Lymphoma Myeloma Leuk; ePub 2017 May 12; Miller, et al

Ruxolitinib’s benefit in patients with myelofibrosis can be assessed using a number of methods that are easily accessed in the community setting, according to a post hoc analysis of data from COMFORT-I trial involving 150 individuals.

Investigators evaluated changes over 12 weeks in spleen size, patient-reported outcomes, body weight, and serum albumin levels in 5 ruxolitinib-treated subgroups divided based on spleen length. Among the results:

  • Ruxolitinib was linked with improved spleen volume in all subgroups, including those with worsening spleen length.
  • Body weight and serum albumin levels also improved.
  • Greater reductions in spleen length were linked with prolonged overall survival.


Miller C, Komrokji R, Mesa R, Sun W, Montgomery M, Verstovsek S. Practical measures of clinical benefit with ruxolitinib therapy: An exploratory analysis of COMFORT-I. [Published online ahead of print May 12, 2017]. Clin Lymphoma Myeloma Leuk. doi:10.1016/j.clml.2017.05.015.